



BIO Atlanta: Visit Receptor Logic at the Texas Pavilion, Booth #4633

Receptor Logic, Inc. Launches New Website

Site showcases company's new antibody platform, TCRm™

Austin and Abilene, TX – May 13, 2009 – Biopharmaceutical company Receptor Logic, Inc. announced today the unveiling of its newly redesigned website, www.receptorlogic.com. Expanded sales and partnership activities in 2008 necessitated an improved website providing clear navigation to the three business areas comprising the Receptor Logic model: therapeutic antibodies, assay services and research reagents.

Receptor Logic has developed a new antibody platform, known as T-Cell Receptor mimic (TCRm™) antibodies, that enables new therapeutic monoclonal antibody products and assists cancer drug developers in characterizing the activities of their investigational active immunotherapies drugs, including cancer vaccines. Both applications enable new product development and promise to improve patient results. With the website Receptor Logic will provide life science researchers improved access to the broad applications of its proprietary TCRm technology.

"Our online visitors will now experience a more vibrant and seamless view of the power TCRm technology offers," says Gregory Pogue, Ph.D., President of Receptor Logic, Inc. "Our TCRm technology provides expanded therapeutic access to disease by targeting an entirely new-class of disease-specific biomarkers, enabling measurement of the potency of vaccine immunotherapies, and providing attractive new products for immunology research."

In addition to seeking strategic co-development partnerships with leading biotechnology and pharmaceutical companies, Receptor Logic also intends to utilize the website as a platform presenting its TCRm research reagent products for direct sale.

TCRm Technology

Receptor Logic has invented a new platform for monoclonal antibody therapeutics. Monoclonal antibody (mAb) therapies are remarkably effective in addressing cancer, chronic inflammatory conditions and pathogen infections. TCRm technology blends the impressive specificity of traditional mAb therapies while targeting an entire new class of disease-specific biomarkers for underserved patient populations. Receptor Logic is exploring partnerships to accelerate development of lead TCRm candidates.

Receptor Logic's TCRm antibodies recognize many peptide antigens used in pharmaceutical and biopharmaceutical discovery and product development

--more--

Page 2 of 2 – Receptor Logic, Inc. Launches New Website

research. The TCRm antibodies can immediately integrate into and provide a quantitative baseline for a number of established assays, including:

- Vaccine potency measurements
- Immunocytochemical staining
- Flow cytometry
- ELISA
- Antigen priming
- ELISpot
- Cytotoxic T-lymphocyte assays

An online catalog and ordering form can be accessed on the Receptor Logic website allowing rapid product access and integration into focused research programs to meet research goals and to add to therapeutic pipelines.

About Receptor Logic, Inc.

Receptor Logic, Inc. is a biopharmaceutical company specializing in high-quality T-Cell Receptor mimic (TCRm) monoclonal antibodies that offer valuable insight into how the immune system interacts with a diseased cell, yielding better immunology research, better clinical diagnostics, and better therapies such as monoclonal antibodies and vaccines. Receptor Logic, Inc. is funded and managed by life sciences technology investment and management company, [Emergent Technologies, Inc.](#) For more information, please visit the company website www.receptorlogic.com.

###

Contact:

Sandra Oak
Nsight Public Relations
Phone: 321-591-1508
Email: soak@nsightpr.com